Publicaciones científicas de Oryzon

En Oryzon realizamos investigación de vanguardia en los campos oncológico y neurodegenerativo.


Epigenética

1. ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia. Maes T, Mascaró C, Tirapu I, Estiarte A, Ciceri F, Lunardi S, Guibourt N, Perdones A, Lufino MMP, Somervaille TCP, Wiseman DH, Duy C, Melnick A, Willekens C, Ortega A, Martinell M, Valls N, Kurz G, Fyfe M, Castro-Palomino JC, Buesa C. Cancer Cell. 2018 Mar 12;33(3):495-511.e12. doi: 10.1016/j.ccell.2018.02.002. Epub 2018 Mar 1. PMID: 29502954

2. Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons. Rivers A, Vaitkus K, Jagadeeswaran R, Ruiz MA, Ibanez V, Ciceri F, Cavalcanti F, Molokie RE, Saunthararajah Y, Engel JD, DeSimone J, Lavelle D. Exp Hematol. 2018 Aug 17. pii: S0301-472X(18)30750-1. doi: 10.1016/j.exphem.2018.08.003. [Epub ahead of print] PMID: 30125603

3. Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies. Ciceri F, Rotllant D, Maes T. Curr Pharm Des. 2017; 23(5):839-857. doi: 10.2174/1381612823666170124121140. Review. PMID: 28120717

4. KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease Maes T, Mascaró C, Ortega A, Lunardi S, Ciceri F, P Somervaille TC, Buesa C. Epigenomics, 2015 Jun;7(4):609-26. doi: 10.2217/epi.15.9 Review.

5. Advances in the development of histone lysine demethylase inhibitors. Maes T, Carceller E, Salas J, Ortega A, Buesa C. Curr Opin Pharmacol. 2015 Jun 5;23:52-60. doi: 10.1016/j.coph.2015.05.009. Review. PMID: 26057211

6. Activity of highly selective LSD1 inhibitors in HCT-116 xenograft mice. T. Maes, J. Castro, A. Ortega and N. Guibourt Journal of Clinical Oncology, 2010 ASCO Annual Meeting Abstracts. Vol 28, No 15_suppl (May 20 Supplement), 2010: e13663

Genómica / Bioinformática / Biomarcadores

1. Molecular diagnostics of endometrial cancer from uterine aspirate. Pérez-Sánchez C, Colas E, Cabrera S, Falcon O, Sanchez-del-Río A, García E, Fernández-de-Castillo L, Muruzabal JC, Alvarez E, Fiol G, González C, Torrejón R, Moral E, Campos M, Repollés M, Carreras R, Jiménez-López J, Xercavins J, Aibar E, Perdones-Montero A, Lalanne E, Palicio M, Maes T, et al. Int J Cancer. 2013,133: 2383-2391.

2. Molecular markers of endometrial carcinoma detected in uterine aspirates. Colas E, Perez C, Cabrera S, Pedrola N, Monge M, Castellvi J, Eyzaguirre F, Gregorio J, Ruiz A, Llaurado M, Rigau M, Garcia M, Ertekin T, Montes M, Lopez-Lopez R, Carreras R, Xercavins J, Ortega A, Maes T, et al.. Int J Cancer. 2011,129:2435--2444.

3. Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer. Pio R, Blanco D, Pajares MJ, Aibar E, Durany O, Ezponda T, Agorreta J, Gomez-Roman J, Anton MA, Rubio A, Lozano MD, López-Picazo JM, Subirada F, Maes T, Montuenga LM. BMC Genomics. 2010 Jun 3;11:352.

4. DNA Chip Technology in Brain Banks: Confronting a Degrading World. Buesa, Carlos Maes, Tamara; Subirada, Francesc; Barrachina, Marta; Ferrer, Isidro Journal of Neuropathology & Experimental Neurology: October 2004 - Volume 63 - Issue 10 - p 1003–1014